Article Text

Download PDFPDF
Ferritin—a promising biomarker in MASLD
  1. Heinz Zoller1,2,
  2. Herbert Tilg3
  1. 1 Department of Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University of Innsbruck, Innsbruck, Tirol, Austria
  2. 2 Christian Doppler Laboratory on Iron and Phosphate Biology, Christian Doppler Forschungsgesellschaft, Innsbruck, Tirol, Austria
  3. 3 Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medizinische Universitat Innsbruck, Innsbruck, Tirol, Austria
  1. Correspondence to Dr Heinz Zoller, Department of Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University of Innsbruck, Innsbruck, Tirol, Austria; heinz.zoller{at}i-med.ac.at

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Human ferritins are expressed in essentially all cells of the human body. From an evolutionary perspective, human ferritins are part of a diverse ferritin-like superfamily—the ‘rubrerythins’, that include plant ferritins and bacterioferritins, where they cover a wide range of biological functions.1 Although best known as a 24-meric intracellular iron storage protein, ferritin is also present in the human circulation, where its biological functions are still being unravelled. Recent studies have shown that ferritin can be actively secreted from cells in extracellular vesicles (EVs). These ferritin-laden EVs can contribute to the pathogenesis of liver steatosis and fibrogenesis by shuttling iron from hepatocytes to hepatic stellate cells.2 Hence, in patients with metabolic syndrome, serum ferritin is more than a surrogate of body iron status.3 Especially in metabolic dysfunction-associated steatotic liver disease (MASLD), which is the now preferred term for a disease that has until recently been known as non-alcoholic fatty liver disease (NAFLD), serum ferritin is strongly correlated with liver fibrosis and disease progression.4 5

Inflammation is a hallmark of progressive MASLD and liver inflammation is a key feature of metabolic dysfunction-associated steatohepatitis (MASH). Although underlying mechanisms responsible for initiation of inflammation in MASLD remain somewhat unclear, it is increasingly accepted that various hits such as lipotoxicity, endoplasmic reticulum stress, insulin resistance or gut dysbiosis contribute to liver and/or systemic inflammation.6 Gut-derived bacterial components such as endotoxin might especially play …

View Full Text

Footnotes

  • Contributors HZ amended the first draft of the manuscript, reviewed and approved it. HT wrote a first draft of the manuscript, reviewed and approved it.

  • Funding CD laboratory on Iron and Phosphate Biology.

  • Competing interests HT is an Editor of Gut.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Hepatology
    Angelo Armandi Tiziana Sanavia Ramy Younes Gian Paolo Caviglia Chiara Rosso Olivier Govaere Antonio Liguori Paolo Francione Rocìo Gallego-Duràn Javier Ampuero Grazia Pennisi Rocio Aller Dina Tiniakos Alastair Burt Ezio David Fabio Vecchio Marco Maggioni Daniela Cabibi Duncan McLeod Maria Jesus Pareja Marco Y W Zaki Antonio Grieco Per Stål Stergios Kechagias Anna Ludovica Fracanzani Luca Valenti Luca Miele Piero Fariselli Mohammed Eslam Salvatore Petta Hannes Hagström Jacob George Jörn M Schattenberg Manuel Romero-Gómez Quentin Mark Anstee Elisabetta Bugianesi